Roslyn B Mannon

List of Publications by Year
in descending order

164 papers	7,875 citations	61945 43 h-index	56687 83 g-index
174 all docs	174 docs citations	174 times ranked	7637 citing authors

#	Article	IF	Citations
1	Evidence for Antibody-Mediated Injury as a Major Determinant of Late Kidney Allograft Failure. Transplantation, 2010, 90, 68-74.	0.5	447
2	The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cellâ€“ and antibody-mediated rejection. American Journal of Transplantation, 2020, 20, 2318-2331.	2.6	437
3	Immunocompetent T-Cells with a Memory-Like Phenotype are the Dominant Cell Type Following Antibody-Mediated T-Cell Depletion. American Journal of Transplantation, 2005, 5, 465-474.	2.6	435
4	RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H). Transplantation, 2003, 76, 120-129.	0.5	413
5	Metformin reverses established lung fibrosis in a bleomycin model. Nature Medicine, 2018, 24, 1121-1127.	15.2	411
6	Cell-Free DNA and Active Rejection in Kidney Allografts. Journal of the American Society of Nephrology: JASN, 2017, 28, 2221-2232.	3.0	365
7	Assessing Relative Risks of Infection and Rejection: A Meta-analysis using an Immune Function Assay. Transplantation, 2006, 82, 663-668.	0.5	294
8	Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. Journal of Clinical Investigation, 1999, 104, 1693-1701.	3.9	270
9	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. American Journal of Transplantation, 2018, 18, 1604-1614.	2.6	205
10	Inflammation in Areas of Tubular Atrophy in Kidney Allograft Biopsies: A Potent Predictor of Allograft Failure. American Journal of Transplantation, 2010, 10, 2066-2073.	2.6	199
11	Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US. JAMA Internal Medicine, 2022, 182, 153.	2.6	182
12	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group. Transplantation, 2020, 104, 911-922.	0.5	172
13	Obesity increases the risk of end-stage renal disease among living kidney donors. Kidney International, 2017, 91, 699-703.	2.6	136
14	Delayed Graft Function: The AKI of Kidney Transplantation. Nephron, 2018, 140, 94-98.	0.9	130
15	Functionally Significant Renal Allograft Rejection Is Defined by Transcriptional Criteria. American Journal of Transplantation, 2005, 5, 573-581.	2.6	125
16	Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet, The, 2002, 360, 1662-1664.	6.3	116
17	Results from a Human Renal Allograft Tolerance Trial Evaluating T-Cell Depletion with Alemtuzumab Combined with Deoxyspergualin. Transplantation, 2005, 80, 1051-1059.	0.5	115
18	A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation, 2016, 100, 184-193.	0.5	110

#	Article	IF	Citations
19	Late Kidney Allograft Loss. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, S56-S67.	2.2	101
20	Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheumatology, The, 2022, 4, e33-e41.	2.2	96
21	Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation, 2002, 74, 916-923.	0.5	95
22	A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney International, 2021, 100, 196-205.	2.6	95
23	Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. Journal of Clinical Investigation, 2006, 116, 769-774.	3.9	90
24	Immune Cells in a Mouse Airway Model of Obliterative Bronchiolitis. American Journal of Respiratory Cell and Molecular Biology, 1998, 19, 379-386.	1.4	88
25	Immunosuppression Regimen and the Risk of Acute Rejection in HIV-Infected Kidney Transplant Recipients. Transplantation, 2014, 97, 446-450.	0.5	83
26	Macrophages. Current Opinion in Organ Transplantation, 2012, 17, 20-25.	0.8	76
27	NPHP1 (Nephrocystin-1) Gene Deletions Cause Adult-Onset ESRD. Journal of the American Society of Nephrology: JASN, 2018, 29, 1772-1779.	3.0	74
28	Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report. American Journal of Transplantation, 2020, 20, 2652-2668.	2.6	70
29	Donor genomics influence graft events: The effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. Kidney International, 2004, 66, 1686-1693.	2.6	64
30	Chemokines and Their Receptors in Human Renal Allotransplantation. Transplantation, 2011, 91, 70-77.	0.5	59
31	Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications. journal of applied laboratory medicine, The, 2017, 2, 309-321.	0.6	59
32	Chronic rejection of mouse kidney allografts. Kidney International, 1999, 55, 1935-1944.	2.6	57
33	Survey of US Living Kidney Donation and Transplantation Practices in the COVID-19 Era. Kidney International Reports, 2020, 5, 1894-1905.	0.4	54
34	Genetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantation. Transplantation, 2011, 91, 309-316.	0.5	52
35	The prognostic value of left ventricular mechanical dyssynchrony using gated myocardial perfusion imaging in patients with end-stage renal disease. Journal of Nuclear Cardiology, 2014, 21, 739-746.	1.4	50
36	Access to Kidney Transplantation among HIV-Infected Waitlist Candidates. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 467-475.	2.2	50

#	Article	IF	Citations
37	Strategies for minimizing immunosuppression in kidney transplantation. Transplant International, 2005, 18, 2-14.	0.8	48
38	Obesity following kidney transplantation and steroid avoidance immunosuppression. Clinical Transplantation, 2008, 22, 354-359.	0.8	46
39	The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable?. Current Transplantation Reports, 2015, 2, 113-121.	0.9	46
40	Inpatient Mortality Among Solid Organ Transplant Recipients Hospitalized for Sepsis and Severe Sepsis. Clinical Infectious Diseases, 2016, 63, 186-194.	2.9	46
41	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 475-483.	2.6	45
42	Apolipoprotein L1 and Chronic Kidney Disease Risk in Young Potential Living Kidney Donors. Annals of Surgery, 2018, 267, 1161-1168.	2.1	44
43	Subclinical inflammation phenotypes and long-term outcomes after pediatric kidney transplantation. American Journal of Transplantation, 2018, 18, 2189-2199.	2.6	44
44	ENHANCED T CELL CYTOKINE GENE EXPRESSION IN MOUSE AIRWAY OBLITERATIVE BRONCHIOLITIS1. Transplantation, 2000, 69, 399-405.	0.5	43
45	Late graft failure after kidney transplantation as the consequence of late versus early events. American Journal of Transplantation, 2018, 18, 1158-1167.	2.6	39
46	Practicing With Uncertainty: Kidney Transplantation During the COVID-19 Pandemic. American Journal of Kidney Diseases, 2021, 77, 777-785.	2.1	39
47	POLYOMAVIRUS NEPHROPATHY: WHAT HAVE WE LEARNED?1. Transplantation, 2004, 77, 1313-1318.	0.5	38
48	COVID-19 in Solid Organ Transplantation: Results of the National COVID Cohort Collaborative. Transplantation Direct, 2021, 7, e775.	0.8	38
49	Effect of a Mobile Web App on Kidney Transplant Candidates' Knowledge About Increased Risk Donor Kidneys. Transplantation, 2017, 101, 1167-1176.	0.5	37
50	Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups. American Journal of Transplantation, 2019, 19, 2795-2804.	2.6	35
51	Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigenâ€“matching priorities to improve transplant outcomes? An expert review and recommendations. Kidney International, 2021, 100, 1012-1022.	2.6	35
52	The road to tolerance: renal transplant tolerance induction in nonhuman primate studies and clinical trials. Transplant Immunology, 2004, 13, 87-99.	0.6	34
53	Elevated expression levels of ANXA11, integrins Î²3 and Î±3, and TNFâ€Î± contribute to a candidate proteomic signature in urine for kidney allograft rejection. Proteomics - Clinical Applications, 2011, 5, 311-321.	0.8	34
54	Lack of Renal Dopamine D5 Receptors Promotes Hypertension. Journal of the American Society of Nephrology: JASN, 2011, 22, 82-89.	3.0	34

#	Article	IF	Citations
55	Immune monitoring and biomarkers to predict chronic allograft dysfunction. Kidney International, 2010, 78, S59-S65.	2.6	32
56	Tacrolimus trough and dose intraâ€patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. Clinical Transplantation, 2018, 32, e13424.	0.8	30
57	First NIH/Office of Rare Diseases Conference on Cystinosis: past, present, and future. Pediatric Nephrology, 2005, 20, 452-454.	0.9	29
58	Beyond Histology: Novel Tools to Diagnose Allograft Dysfunction. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 358-366.	2.2	29
59	Peptide YY/neuropeptide Y Y1 receptor expression in the epithelium and mucosal nerves of the human colon. Regulatory Peptides, 1999, 83, 11-19.	1.9	27
60	Deficiency of 5-Lipoxygenase Accelerates Renal Allograft Rejection in Mice. Journal of Immunology, 2001, 167, 6631-6636.	0.4	27
61	Associations of ABCB1 3435C>T and IL-10-1082G>A Polymorphisms With Long-Term Sirolimus Dose Requirements in Renal Transplant Patients. Transplantation, 2011, 92, 1342-1347.	0.5	27
62	Cyclosporine-mediated allograft fibrosis is associated with micro-RNA-21 through AKT signaling. Transplant International, 2015, 28, 232-245.	0.8	27
63	REJECTION OF KIDNEY ALLOGRAFTS BY MHC CLASS I-DEFICIENT MICE. Transplantation, 1995, 59, 746-755.	0.5	24
64	A reproducible mouse model of chronic allograft nephropathy with vasculopathy. Kidney International, 2012, 82, 1231-1235.	2.6	24
65	Genomic and proteomic fingerprints of acute rejection in peripheral blood and urine. Transplantation Reviews, 2015, 29, 60-67.	1.2	23
66	Lessons Learned: Early Termination of a Randomized Trial of Calcineurin Inhibitor and Corticosteroid Avoidance Using Belatacept. American Journal of Transplantation, 2017, 17, 2712-2719.	2.6	23
67	Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. Pharmacogenomics, 2018, 19, 175-184.	0.6	23
68	Chronic Allograft Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1723-1729.	2.2	23
69	The Advancing American Kidney Health (AAKH) Executive Order: Promise and Caveats for Expanding Access to Kidney Transplantation. Kidney360, 2020, 1, 557-560.	0.9	23
70	Identification of Strategies to Facilitate Organ Donation among African Americans using the Nominal Group Technique. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 286-293.	2.2	22
71	Immunodiagnostics: Evaluation of Functional T-Cell Immunocompetence in Whole Blood Independent of Circulating Cell Numbers. Journal of Immunotoxicology, 2007, 4, 225-232.	0.9	21
72	Successful Renal Transplantation in a Patient with Congenital Generalized Lipodystrophy: A Case Report. American Journal of Transplantation, 2004, 4, 447-449.	2.6	20

#	Article	IF	Citations
73	Long-term follow-up of the DeKAF cross-sectional cohort study. American Journal of Transplantation, 2019, 19, 1432-1443.	2.6	20
74	ALTERED INTRAGRAFT IMMUNE RESPONSES AND IMPROVED RENAL FUNCTION IN MHC CLASS II-DEFICIENT MOUSE KIDNEY ALLOGRAFTS12. Transplantation, 2000, 69, 2137-2143.	0.5	20
75	Impact of Subclinical Borderline Inflammation on Kidney Transplant Outcomes. Transplantation Direct, 2021, 7, e663.	0.8	19
76	Establishing a Core Outcome Measure for Graft Health. Transplantation, 2018, 102, 1358-1366.	0.5	18
77	Apolipoprotein L1: role in the evaluation of kidney transplant donors. Current Opinion in Nephrology and Hypertension, 2020, 29, 645-655.	1.0	18
78	Inflammation in areas of fibrosis: The DeKAF prospective cohort. American Journal of Transplantation, 2020, 20, 2509-2521.	2.6	18
79	The risk and consequences of breakthrough SARS-CoV-2 infection in solid organ transplant recipients relative to non-immunosuppressed controls. American Journal of Transplantation, 2022, 22, 2418-2432.	2.6	18
80	Alterations In Renal Interleukin-1 Production During Kidney Transplant Rejection In The Rat. Transplantation, 1993, 56, 1157-1161.	0.5	17
81	Noninvasive methods to assess the risk of kidney transplant rejection. Expert Review of Clinical Immunology, 2009, 5, 535-546.	1.3	17
82	Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies. Transplantation, 2019, 103, 1131-1139.	0.5	17
83	The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement. American Journal of Transplantation, 2019, 19, 625-632.	2.6	17
84	Analysis of 75 Candidate SNPs Associated With Acute Rejection in Kidney Transplant Recipients: Validation of rs2910164 in MicroRNA MIR146A. Transplantation, 2019, 103, 1591-1602.	0.5	16
85	Avoidance of CNI and steroids using belataceptâ€"Results of the Clinical Trials in Organ Transplantation 16 trial. American Journal of Transplantation, 2020, 20, 3599-3608.	2.6	16
86	i-IFTA and chronic active T cellâ€“mediated rejection: A tale of 2 (DeKAF) cohorts. American Journal of Transplantation, 2021, 21, 1866-1877.	2.6	16
87	Dynamic Response of Donor-Derived Cell-Free DNA Following Treatment of Acute Rejection in Kidney Allografts. Kidney360, 2021, 2, 729-736.	0.9	16
88	Operational challenges in the COVIDâ€19 era: Asymptomatic infections and vaccination timing. Clinical Transplantation, 2021, 35, e14437.	0.8	16
89	Inducible nitric oxide synthase promotes cytokine expression in cardiac allografts but is not required for efficient rejection. Journal of Heart and Lung Transplantation, 1999, 18, 819-827.	0.3	15
90	Absence of donor MHC antigen expression ameliorates chronic kidney allograft rejection. Kidney International, 2002, 62, 290-300.	2.6	15

#	Article	IF	Citations
91	Repeat kidney transplant recipients with active rejection have elevated donor-derived cell-free DNA. American Journal of Transplantation, 2019, 19, 1597-1598.	2.6	15
92	Challenges of calcineurin inhibitor withdrawal following combined pancreas and kidney transplantation: Results of a prospective, randomized clinical trial. American Journal of Transplantation, 2020, 20, 1668-1678.	2.6	15
93	Inhibition of Prolyl-4-Hydroxylase Ameliorates Chronic Rejection of Mouse Kidney Allografts. American Journal of Transplantation, 2003, 3, 396-402.	2.6	14
94	Idiopathic intracranial hypertension following kidney transplantation: A case report and review of the literature. Pediatric Transplantation, 2005, 9, 545-550.	0.5	14
95	THE INTRAGRAFT CD8+ T CELL RESPONSE IN RENAL ALLOGRAFT REJECTION IN THE MOUSE1,2. Transplantation, 1996, 62, 96-104.	0.5	14
96	Detection and Localization of Proteinuria by Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using MS325. Journal of the American Society of Nephrology: JASN, 2005, 16, 1752-1757.	3.0	13
97	The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population. American Journal of Transplantation, 2019, 19, 2262-2273.	2.6	13
98	Sex and organ-specific risk of major adverse renal or cardiac events in solid organ transplant recipients with COVID-19. American Journal of Transplantation, 2022, 22, 245-259.	2.6	13
99	Stimulation of Thymocyte Proliferation by Phosphorothioate DNA Oligonucleotides. Cellular Immunology, 2000, 201, 14-21.	1.4	12
100	Surgical transplant physical examination: Correlation of renal resistance index and biopsy-proven chronic allograft nephropathy. Journal of the American College of Surgeons, 2005, 200, 552-556.	0.2	11
101	C3 Polymorphisms and Outcomes of Renal Allografts. New England Journal of Medicine, 2009, 360, 2477-2479.	13.9	11
102	Probabilistic (Bayesian) Modeling of Gene Expression in Transplant Glomerulopathy. Journal of Molecular Diagnostics, 2010, 12, 653-663.	1.2	11
103	Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing. Pharmacogenomics Journal, 2019, 19, 375-389.	0.9	11
104	Gene targeting: Applications in transplantation research. Kidney International, 1999, 56, 18-27.	2.6	10
105	Optimal Cutoff Point for Immunoperoxidase Detection of C4d in the Renal Allograft: Results From a Multicenter Study. Transplantation, 2010, 90, 1099-1105.	0.5	10
106	Evaluation of tacrolimus abbreviated areaâ€underâ€theâ€curve monitoring in renal transplant patients who are potientially at risk for adverse events. Clinical Transplantation, 2010, 24, 557-563.	0.8	10
107	Associations of ABCB1 and IL-10 Genetic Polymorphisms With Sirolimus-Induced Dyslipidemia in Renal Transplant Recipients. Transplantation, 2012, 94, 971-977.	0.5	10
108	Acute Kidney Injury in Kidney Transplants: New Insights. Nephron, 2019, 143, 193-196.	0.9	10

#	Article	IF	Citations
109	The COVIDâ€19 pandemic: A community approach. Clinical Transplantation, 2020, 34, e14059.	0.8	10
110	Low-density array PCR analysis of reperfusion biopsies: an adjunct to histological analysis. Nephrology Dialysis Transplantation, 2010, 25, 4077-4086.	0.4	9
111	Diagnostic Tools for Monitoring Kidney Transplant Recipients. Seminars in Nephrology, 2007, 27, 462-478.	0.6	8
112	Reply to â€œGenetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantationâ€. Transplantation, 2012, 93, e41-e42.	0.5	8
113	The Banff schema for antibody-mediated rejection: Lost in translation?. American Journal of Transplantation, 2019, 19, 9-10.	2.6	7
114	CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients. Pediatric Transplantation, 2019, 23, e13494.	0.5	7
115	WNT pathway signaling is associated with microvascular injury and predicts kidney transplant failure. American Journal of Transplantation, 2019, 19, 2833-2845.	2.6	7
116	Avoiding surveillance biopsy: Use of a noninvasive biomarker assay in a realâ€life scenario. Clinical Transplantation, 2021, 35, e14145.	0.8	7
117	COVIDâ€19 test result reporting for deceased donors: Emergent policies, logistical challenges, and future directions. Clinical Transplantation, 2021, 35, e14280.	0.8	7
118	Allograft Fibrosis-Unmasking the Players at the Dance. American Journal of Transplantation, 2010, 10, 201-202.	2.6	6
119	Necroptosis in Solid Organ Transplantation: A Missing Link to Immune Activation?. American Journal of Transplantation, 2013, 13, 2785-2786.	2.6	6
120	Meeting report of the STAR-Sensitization in Transplantation Assessment of Risk: NaÃ¯ve Abdominal Transplant Organ subgroup focus on kidney transplantation. American Journal of Transplantation, 2018, 18, 2120-2134.	2.6	6
121	Sex matters: COVID-19 in kidney transplantation. Kidney International, 2021, 99, 555-558.	2.6	6
122	Bioenergetic maladaptation and release of HMGB1 in calcineurin inhibitor-mediated nephrotoxicity. American Journal of Transplantation, 2021, 21, 2964-2977.	2.6	6
123	Disparities in Access to Preemptive Repeat Kidney Transplant: Still Missing the Mark?. Kidney360, 2022, 3, 144-152.	0.9	6
124	Exacerbation of Racial Disparities in Living Donor Kidney Transplantation During the COVID-19 Pandemic. Kidney360, 2022, 3, 1089-1094.	0.9	6
125	Hyperrenin-Hyperaldosterone-Dependent Malignant Hypertension in Polyarteritis Nodosa. Southern Medical Journal, 1993, 86, 1400-1402.	0.3	5
126	Islet transplantation: need for a time-out?. Nature Clinical Practice Nephrology, 2008, 4, 660-661.	2.0	5

#	Article	IF	Citations
127	T cellâ€“mediated rejection in kidney transplant recipients: The end(point) is also the beginning. American Journal of Transplantation, 2022, 22, 683-684.	2.6	5
128	Understanding and Overcoming Financial Risks for Living Organ Donors. American Journal of Kidney Diseases, 2022, 79, 159-161.	2.1	5
129	Deceased Donor Procurement Biopsy Practices, Interpretation, and Histology-Based Decision-Making: A Survey of US Kidney Transplant Centers. Kidney International Reports, 2022, 7, 1268-1277.	0.4	5
130	Lymphocyte depletion for kidney transplantation: back to the past?. Nature Clinical Practice Nephrology, 2008, 4, 534-535.	2.0	4
131	A Case of Late Kidney Allograft Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1884-1889.	2.2	4
132	The effect of renal transplantation on left ventricular function, electrocardiography, and mechanical synchrony by gated myocardial perfusion imaging. Journal of Nuclear Cardiology, 2019, 26, 1962-1970.	1.4	4
133	Premature Death in Kidney Transplant Recipients: The Time for Trials is Now. Journal of the American Society of Nephrology: JASN, 2022, 33, 665-673.	3.0	4
134	Delayed autotransplantation of a solitary kidney facilitated by pump perfusion preservation. Surgery, 2003, 133, 438-439.	1.0	3
135	Leflunomide Therapy in Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 652-653.	2.2	3
136	Thrombotic Microangiopathy in a Transplant Recipient. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1251-1253.	2.2	3
137	Post-Transplant Lymphoproliferative Disorder in a Kidney Transplant Recipient. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 751-753.	2.2	3
138	Pharmacogenomics in kidney transplant recipients and potential for integration into practice. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1457-1465.	0.7	3
139	Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry. Journal of Clinical Pharmacology, 2021, 61, 1035-1044.	1.0	3
140	Banff and ABMR: Are we going in the right direction?. American Journal of Transplantation, 2021, 21, 2321-2322.	2.6	3
141	Living Organ Donor Perspectives and Sources of Hesitancy about COVID-19 Vaccines. Kidney360, 2021, 2, 1132-1140.	0.9	3
142	Time for increased awareness of sex as a biological variable in transplantation. American Journal of Transplantation, 2021, 21, 3215-3216.	2.6	3
143	Kidney transplantation with rabbit antithymocyte globulin and sirolimus monotherapy. Lancet, The, 2003, 361, 969-970.	6.3	2
144	Use of Checkpoint Inhibitors in a Kidney Transplant Recipient with Metastatic Cancer. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1190-1192.	2.2	2

#	Article	IF	Citations
145	Disparities in Deceased Organ Donor Research Authorization: Experience at One Organ Procurement Organization and Call for National Conversations. Kidney International Reports, 2021, 6, 2331-2337.	0.4	2
146	Incorporation of sex and gender guidelines into transplantation literature. Transplantation, 2021, Publish Ahead of Print, e261-e262.	0.5	2
147	Emerging biomarkers in kidney transplantation and challenge of clinical implementation. Current Opinion in Organ Transplantation, 2021, Publish Ahead of Print, 15-21.	0.8	2
148	From the Cradle to the Grave: The Life Cycle of Gender Disparities in Kidney Care. Kidney International Reports, 2022, 7, 363-365.	0.4	2
149	Abnormal timeâ€zero histology is predictive of kidney transplant outcomes. Clinical Transplantation, 2022, 36, e14676.	0.8	2
150	Care of the Kidney Transplant Recipient. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, S27-S28.	2.2	1
151	Establishing a Core Outcome Measure for Graft Health. Transplantation, 2018, 102, S82.	0.5	1
152	Industry partnerships in transplantation: How should AJT manage the inevitable conflict of interest?. American Journal of Transplantation, 2021, 21, 1988-1989.	2.6	1
153	Malignancies Before and After Transplantation. , 2010, , 311-326.		1
154	Is It Time for Operation Warp Speed in Transplant Research?. Transplantation Direct, 2020, 6, e619.	0.8	1
155	Data carve out in the midst of the <scp>COVID</scp> â€19 pandemic. American Journal of Transplantation, 0, , .	2.6	1
156	DONOR TRACHEAS LACKING MHC PROTEINS HAVE DIMINISHED AIRWAY OBLITERATION.. Transplantation, 2000, 69, S345.	0.5	0
157	Obesity Is Associated with Increased Risk of Mortality among Living Kidney Donors. Transplantation, 2018, 102, S42.	0.5	0
158	A glossary for patient care and scientific dialogue from KDIGO. American Journal of Transplantation, 2021, 21, 458-459.	2.6	0
159	Risk Prediction for Delayed Allograft Function. Transplantation, 2021, Publish Ahead of Print, .	0.5	0
160	Novel Phenotypes for Acute Kidney Transplant Rejection Using Semi-Supervised Clustering. Journal of the American Society of Nephrology: JASN, 2021, 32, 2387-2388.	3.0	0
161	ACTIVATION OF MURINE THYMOCYTES BY DNA OLIGONUCLEOTIDES. Transplantation, 1999, 67, S128.	0.5	0
162	Modernization of Chronic Allograft Injury Research: Better Biomarkers, Better Studies, Better Outcomes. Clinical Transplants, 2015, 31, 211-225.	0.2	0

#	Article	IF	Citations
163	Gut microbial biomarkers for predicting adverse outcomes in people with chronic kidney disease. The Cochrane Library, 2022, 2022, .	1.5	0
164	Sex and gender as predictors for allograft and patient-relevant outcomes after kidney transplantation. The Cochrane Library, 2022, 2022, .	1.5	0